Levosimendan Zentiva (Levosimendan)

• Levosimendan is used in the management of acute heart failure syndromes by enhancing myocardial contractility and reducing afterload.
• Acute decompensated heart failure: improves cardiac output and relieves symptoms in hospitalized patients.
• Cardiogenic shock: provides hemodynamic support when conventional therapies are insufficient.
• Severe left ventricular dysfunction: enhances contractility to stabilize patients awaiting further intervention.

• Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium ions, which augments myocardial contractile force without raising intracellular calcium concentration. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing preload and afterload. These combined actions improve cardiac output while limiting oxygen demand. The drug’s effect is dose‑dependent and reversible, allowing titration under hemodynamic monitoring.

Levosimendan may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects

• Hypotension: drop in blood pressure, especially after rapid infusion.
• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal upset.
• Arrhythmia: ventricular or atrial ectopic beats.

Serious or Rare Side Effects

• Severe hypotension: may require vasopressor support.
• Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion.
• Anaphylactic reaction: rare but potentially life‑threatening hypersensitivity.

When using Levosimendan, clinicians should observe specific safety measures to minimize risk.

• Monitor blood pressure: watch for symptomatic hypotension during and after infusion.
• Assess cardiac rhythm: observe for new or worsening arrhythmias.
• Use with caution in renal impairment: adjust monitoring as drug clearance may be affected.
• Avoid in severe hepatic dysfunction: risk of drug accumulation and heightened effects.
• Contraindicated in patients with known hypersensitivity to levosimendan or its excipients.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with other medications, influencing hemodynamic stability or drug metabolism.

Major Interactions (Avoid)

• Sodium nitroprusside: additive vasodilatory effect may cause profound hypotension.
• Other vasodilators (e.g., nitroglycerin): risk of severe blood pressure fall.
• Beta‑blockers: may blunt the inotropic response of levosimendan.

Moderate Interactions (Monitor Closely)

• Loop diuretics: may exacerbate electrolyte disturbances and affect renal function.
• ACE inhibitors or ARBs: combined effect on blood pressure requires careful titration.